https://news.medxy.ai/zh/bankart-repair-outcomes-2/Medxy AIzh2026-11-01T02:55:06-08:00年轻运动员关节镜下Bankart修复5年结局：复发、重返运动与风险因素 https://news.medxy.ai/ja/five-year-bankart-outcomes/Medxy AIja2026-11-01T02:54:49-08:00若年アスリートにおける軽度glenoid bone lossを伴うarthroscopic Bankart修復術の5年成績：再発、スポーツ復帰、危険因子 https://news.medxy.ai/vi/five-year-bankart-outcomes-2/Medxy AIvi2026-11-01T02:54:24-08:00Kết quả 5 năm sau phẫu thuật Bankart nội soi ở vận động viên trẻ có mất xương ổ chảo tối thiểu: tái phát, quay lại thể thao và yếu tố nguy cơ https://news.medxy.ai/five-year-outcomes-of-arthroscopic-bankart-repair-in-young-athletes-with-minimal-glenoid-bone-loss-recurrence-return-to-sport-and-risk-factors/Medxy AIen2026-11-01T02:54:07-08:00Five-Year Outcomes of Arthroscopic Bankart Repair in Young Athletes With Minimal Glenoid Bone Loss: Recurrence, Return to Sport, and Risk Factors https://news.medxy.ai/zh/age-differences-stroke-outcomes/Medxy AIzh2026-11-01T02:53:28-08:00年龄差异如何影响长期多模式卒中干预结局：LAST-long 试验带来的启示 https://news.medxy.ai/ja/age-impact-stroke-outcomes/Medxy AIja2026-11-01T02:53:08-08:00年齢差が長期多面的脳卒中介入の転帰を左右する：LAST-long試験からの知見 https://news.medxy.ai/vi/age-and-long-term-stroke-rehabilitation/Medxy AIvi2026-11-01T02:52:45-08:00Tuổi ảnh hưởng rõ rệt đến hiệu quả của can thiệp đa mô thức dài hạn sau đột quỵ: phân tích từ thử nghiệm LAST-long https://news.medxy.ai/age-related-differences-influence-outcomes-of-long-term-multimodal-stroke-intervention-insights-from-the-last-long-trial/Medxy AIen2026-11-01T02:52:26-08:00Age-Related Differences Influence Outcomes of Long-Term Multimodal Stroke Intervention: Insights from the LAST-long Trial https://news.medxy.ai/zh/oral-health-liver-cancer-risk/Medxy AIzh2026-11-01T02:51:39-08:00口腔健康与肝癌风险的关联：来自瑞典全国队列研究的启示 https://news.medxy.ai/ja/oral-health-liver-cancer-risk-2/Medxy AIja2026-11-01T02:51:20-08:00口腔衛生は肝癌リスクにどう関わるのか？スウェーデン全国コホート研究が示した新知見 https://news.medxy.ai/vi/oral-health-liver-cancer/Medxy AIvi2026-11-01T02:50:57-08:00Sức khỏe răng miệng có liên quan đến nguy cơ ung thư gan: Những phát hiện từ một nghiên cứu đoàn hệ toàn quốc tại Thụy Điển https://news.medxy.ai/linking-oral-health-to-liver-cancer-risk-insights-from-a-nationwide-swedish-cohort-study/Medxy AIen2026-11-01T02:50:37-08:00Linking Oral Health to Liver Cancer Risk: Insights from a Nationwide Swedish Cohort Study https://news.medxy.ai/zh/mitapivat-sickle-cell-disease/Medxy AIzh2026-11-01T02:49:53-08:00Mitapivat治疗镰状细胞病：一种有望改善溶血性贫血并减少并发症的口服新疗法 https://news.medxy.ai/ja/mitapivat-sickle-cell-disease-2/Medxy AIja2026-11-01T02:49:29-08:00鎌状赤血球症におけるミタピバット：溶血性貧血の改善と合併症減少が期待される新規経口治療 https://news.medxy.ai/vi/mitapivat-sickle-cell-anemia/Medxy AIvi2026-11-01T02:49:03-08:00Mitapivat trong bệnh hồng cầu hình liềm: Liệu pháp đường uống đầy hứa hẹn giúp cải thiện thiếu máu tan máu và giảm biến chứng https://news.medxy.ai/mitapivat-in-sickle-cell-disease-a-promising-oral-therapy-to-improve-hemolytic-anemia-and-reduce-complications/Medxy AIen2026-11-01T02:48:43-08:00Mitapivat in Sickle Cell Disease: A Promising Oral Therapy to Improve Hemolytic Anemia and Reduce Complications https://news.medxy.ai/zh/hydrocephalus-treatment-advances/Medxy AIzh2026-11-01T02:47:56-08:00脑积水治疗新进展：前沿研究与持续挑战 https://news.medxy.ai/ja/hydrocephalus-treatment-research/Medxy AIja2026-11-01T02:47:37-08:00水頭症治療の最前線：新規研究と残された課題 https://news.medxy.ai/vi/hydrocephalus-treatment-advance/Medxy AIvi2026-11-01T02:47:16-08:00Tiền tuyến trong điều trị não úng thủy: Các nghiên cứu mới và những thách thức còn tồn tại https://news.medxy.ai/hydrocephalus-advances-in-treatment-emerging-research-and-ongoing-challenges/Medxy AIen2026-11-01T02:47:04-08:00Hydrocephalus: Advances in Treatment, Emerging Research, and Ongoing Challenges https://news.medxy.ai/zh/antibody-remodeling-antiphospholipid-syndrome/Medxy AIzh2026-11-01T02:46:22-08:00BAFF-APRIL 阻断下抗磷脂综合征中同型特异性自身抗体的重塑 https://news.medxy.ai/ja/isotype-specific-autoantibody-reconstruction/Medxy AIja2026-11-01T02:45:57-08:00BAFF-APRIL遮断による抗リン脂質症候群のアイソタイプ特異的自己抗体再構築 https://news.medxy.ai/vi/isotype-specific-autoantibody-restructuring/Medxy AIvi2026-11-01T02:45:33-08:00Tái cấu trúc autoantibody đặc hiệu theo isotype trong hội chứng kháng phospholipid qua ức chế BAFF-APRIL https://news.medxy.ai/isotype-specific-autoantibody-remodeling-in-antiphospholipid-syndrome-via-baff-april-blockade/Medxy AIen2026-11-01T02:45:12-08:00Isotype-Specific Autoantibody Remodeling in Antiphospholipid Syndrome via BAFF-APRIL Blockade https://news.medxy.ai/zh/energy-recovery-after-heart-transplant/Medxy AIzh2026-11-01T02:44:26-08:00心脏移植后的能量恢复与心肌效率：一项探索性研究的启示 https://news.medxy.ai/ja/energy-recovery-heart-transplantation/Medxy AIja2026-11-01T02:44:04-08:00心臓移植後のエネルギー回復と心筋効率：探索的研究からの知見 https://news.medxy.ai/vi/energy-recovery-for-heart-transplantation/Medxy AIvi2026-11-01T02:43:41-08:00Sự phục hồi năng lượng và hiệu quả cơ tim sau ghép tim: Những hiểu biết từ một nghiên cứu thăm dò https://news.medxy.ai/energetic-recovery-and-myocardial-efficiency-after-heart-transplantation-insights-from-an-exploratory-study/Medxy AIen2026-11-01T02:43:23-08:00Energetic Recovery and Myocardial Efficiency After Heart Transplantation: Insights from an Exploratory Study https://news.medxy.ai/zh/hmme-pdt-vs-pulsed-dye-laser/Medxy AIzh2026-11-01T02:42:35-08:00HMME-PDT 与脉冲染料激光治疗面颈部葡萄酒色斑的疗效与安全性比较：一项大型回顾性研究启示 https://news.medxy.ai/ja/port-wine-stain-treatment/Medxy AIja2026-11-01T02:42:14-08:00顔面・頸部ポートワイン母斑に対するHMME-PDTとパルス色素レーザーの比較：大規模後ろ向き研究からの知見 https://news.medxy.ai/vi/hmme-pdt-vs-pulsed-dye-laser-2/Medxy AIvi2026-11-01T02:41:56-08:00HMME-PDT hay laser nhuộm xung: phương pháp nào hiệu quả và an toàn hơn trong điều trị u máu rượu vang vùng mặt – cổ? https://news.medxy.ai/comparative-effectiveness-and-safety-of-hmme-pdt-versus-pulsed-dye-laser-in-treating-facial-and-neck-port-wine-stains-insights-from-a-large-retrospective-study/Medxy AIen2026-11-01T02:41:37-08:00Comparative Effectiveness and Safety of HMME-PDT Versus Pulsed Dye Laser in Treating Facial and Neck Port-Wine Stains: Insights from a Large Retrospective Study https://news.medxy.ai/zh/arterial-pressure-gradient-in-vasoactive-therapy/Medxy AIzh2026-11-01T02:40:54-08:00危重患者血管活性治疗中肱动脉-桡动脉动脉压梯度的临床意义 https://news.medxy.ai/ja/clinical-significance-of-pressure-gradient/Medxy AIja2026-11-01T02:40:33-08:00昇圧薬治療中の重症患者における上腕動脈－橈骨動脈圧較差の臨床的意義 https://news.medxy.ai/vi/arterial-pressure-gradient/Medxy AIvi2026-11-01T02:40:08-08:00Chênh lệch áp lực động mạch giữa cánh tay và quay ở bệnh nhân nặng dùng thuốc vận mạch: Ý nghĩa lâm sàng https://news.medxy.ai/clinical-implications-of-brachial-to-radial-arterial-pressure-gradients-in-critically-ill-patients-on-vasoactive-therapy/Medxy AIen2026-11-01T02:39:50-08:00Clinical Implications of Brachial-to-Radial Arterial Pressure Gradients in Critically Ill Patients on Vasoactive Therapy https://news.medxy.ai/zh/alcohol-prescribing-gaps/Medxy AIzh2026-11-01T02:39:05-08:00住院出院时酒精使用障碍处方为何偏低？关键预测因素与干预切入点 https://news.medxy.ai/ja/factors-in-aud-medication-prescribing/Medxy AIja2026-11-01T02:38:46-08:00退院時のAUD治療薬処方を左右する要因とは：治療ギャップを埋める鍵を探る https://news.medxy.ai/vi/alcohol-discharge-prescriptions/Medxy AIvi2026-11-01T02:38:24-08:00Đơn thuốc khi xuất viện cho rối loạn sử dụng rượu: Những yếu tố dự báo then chốt để thu hẹp khoảng trống điều trị https://news.medxy.ai/hospital-discharge-prescriptions-for-alcohol-use-disorder-unveiling-key-predictors-to-bridge-the-treatment-gap/Medxy AIen2026-11-01T02:38:04-08:00Hospital Discharge Prescriptions for Alcohol Use Disorder: Unveiling Key Predictors to Bridge the Treatment Gap https://news.medxy.ai/zh/thrombin-responsive-fviii-antibody/Medxy AIzh2026-11-01T02:37:22-08:00凝血酶响应型自我调节FVIII模拟抗体：让血友病A治疗更安全 https://news.medxy.ai/ja/safer-hemophilia-a-treatment/Medxy AIja2026-11-01T02:37:01-08:00より安全な血友病A治療へ：トロンビン応答型の自己調節FVIII模倣抗体 https://news.medxy.ai/vi/safer-hemophilia-treatment/Medxy AIvi2026-11-01T02:36:40-08:00Kháng thể mô phỏng FVIII tự điều hòa đáp ứng thrombin: hướng đi mới giúp điều trị hemophilia A an toàn hơn https://news.medxy.ai/innovative-thrombin-responsive-autoregulated-fviii-mimetic-antibodies-for-safer-hemophilia-a-therapy/Medxy AIen2026-11-01T02:36:22-08:00Innovative Thrombin-Responsive AutoRegulated FVIII-Mimetic Antibodies for Safer Hemophilia A Therapy https://news.medxy.ai/zh/lung-cancer-screening-follow-up/Medxy AIzh2026-11-01T02:35:40-08:00破解社区肺癌筛查随访难题：ACCELL试验带来的启示 https://news.medxy.ai/ja/overcoming-follow-up-barriers/Medxy AIja2026-11-01T02:35:20-08:00地域医療における肺がんスクリーニング後フォローアップの障壁をどう乗り越えるか：ACCELL試験からの示唆 https://news.medxy.ai/vi/overcoming-lung-screening-barriers/Medxy AIvi2026-11-01T02:34:59-08:00Vượt Qua Rào Cản Theo Dõi Sàng Lọc Ung Thư Phổi Trong Chăm Sóc Cộng Đồng: Góc Nhìn Từ Thử Nghiệm ACCELL https://news.medxy.ai/navigating-barriers-to-lung-cancer-screening-follow-up-in-community-care-insights-from-the-accell-trial/Medxy AIen2026-11-01T02:34:42-08:00Navigating Barriers to Lung Cancer Screening Follow-Up in Community Care: Insights from the ACCELL Trial https://news.medxy.ai/zh/glaucoma-visual-field-progression/Medxy AIzh2026-11-01T02:33:58-08:00青光眼视野再次进展：发生率、危险因素与临床意义 https://news.medxy.ai/ja/glaucoma-field-progression-recurrence/Medxy AIja2026-11-01T02:33:40-08:00緑内障の視野進行は再発するのか？発生率・危険因子・臨床的意義を検証 https://news.medxy.ai/vi/glaucoma-visual-field-progression-2/Medxy AIvi2026-11-01T02:33:20-08:00Glaucoma: nguy cơ tái phát tiến triển thị trường, các yếu tố dự báo và ý nghĩa lâm sàng https://news.medxy.ai/recurrent-visual-field-progression-in-glaucoma-incidence-risk-factors-and-clinical-implications/Medxy AIen2026-11-01T02:33:03-08:00Recurrent Visual Field Progression in Glaucoma: Incidence, Risk Factors, and Clinical Implications https://news.medxy.ai/zh/music-perception-hearing-devices/Medxy AIzh2026-11-01T02:32:23-08:00低频退化下音乐音质如何被感知？助听器与人工耳蜗的差异比较 https://news.medxy.ai/ja/low-frequency-sound-perception/Medxy AIja2026-11-01T02:32:07-08:00補聴器と人工内耳でみる低周波数音質知覚：音楽の聴こえ方の違いを検証 https://news.medxy.ai/vi/low-frequency-music-quality/Medxy AIvi2026-11-01T02:31:45-08:00Cảm nhận chất lượng âm nhạc ở dải tần thấp trong các thiết bị hỗ trợ thính giác: So sánh máy trợ thính và ốc tai điện tử https://news.medxy.ai/perception-of-low-frequency-musical-sound-quality-in-hearing-assistive-devices-comparing-hearing-aids-and-cochlear-implants/Medxy AIen2026-11-01T02:31:29-08:00Perception of Low-Frequency Musical Sound Quality in Hearing-Assistive Devices: Comparing Hearing Aids and Cochlear Implants https://news.medxy.ai/zh/pancreatic-fistula-management/Medxy AIzh2026-11-01T02:30:51-08:00远端胰腺切除术后胰瘘与腹腔积液：发生率、临床影响及处理策略 https://news.medxy.ai/ja/pancreatic-fistula-management-2/Medxy AIja2026-11-01T02:30:31-08:00遠位膵切除術後の膵瘻と腹腔内液体貯留：発生率、臨床的影響、管理戦略 https://news.medxy.ai/vi/pancreatic-leak-management/Medxy AIvi2026-11-01T02:30:07-08:00Rò tụy và ổ dịch trong ổ bụng sau cắt tụy xa: Tỷ lệ mắc, ý nghĩa lâm sàng và chiến lược xử trí https://news.medxy.ai/pancreatic-fistula-and-intra-abdominal-fluid-collections-after-distal-pancreatectomy-incidence-clinical-impact-and-management-strategies/Medxy AIen2026-11-01T02:29:49-08:00Pancreatic Fistula and Intra-abdominal Fluid Collections After Distal Pancreatectomy: Incidence, Clinical Impact, and Management Strategies https://news.medxy.ai/zh/early-abortion-follow-up-optimization/Medxy AIzh2026-11-01T02:29:04-08:00新西兰早期药物流产随访方式优化：随机对照试验证实自我评估优于血清bhCG检测 https://news.medxy.ai/ja/early-abortion-follow-up-improvements/Medxy AIja2026-11-01T02:28:46-08:00ニュージーランドで明らかになった早期医療的中絶後フォローアップの改善策：自己評価と血清bhCG検査を比較したランダム化比較試験 https://news.medxy.ai/vi/early-abortion-follow-up/Medxy AIvi2026-11-01T02:28:23-08:00Tăng cường theo dõi sau phá thai nội khoa sớm tại New Zealand: Bằng chứng từ thử nghiệm ngẫu nhiên có đối chứng về tự đánh giá so với xét nghiệm beta-hCG huyết thanh https://news.medxy.ai/enhancing-follow-up-after-early-medical-abortion-in-new-zealand-evidence-from-a-randomised-controlled-trial-on-self-assessment-versus-serum-bhcg-testing/Medxy AIen2026-11-01T02:28:03-08:00Enhancing Follow-Up After Early Medical Abortion in New Zealand: Evidence from a Randomised Controlled Trial on Self-Assessment versus Serum bhCG Testing https://news.medxy.ai/zh/miricorilant-mash-trial/Medxy AIzh2026-11-01T02:27:17-08:00MASH治疗新进展：miricorilant 1b期研究结果积极，间歇给药方案更具潜力 https://news.medxy.ai/ja/miricorilant-for-mash-intermittent-dosing/Medxy AIja2026-11-01T02:26:56-08:00MASH治療の新たな進展：miricorilantの第1b相試験で良好な結果、間欠投与レジメンにさらなる可能性 https://news.medxy.ai/vi/miricorilant-mash-intermittent-dosing/Medxy AIvi2026-11-01T02:26:35-08:00Miricorilant trong viêm gan nhiễm mỡ liên quan rối loạn chức năng chuyển hóa: Kết quả giai đoạn 1b đầy hứa hẹn nhấn mạnh chiến lược dùng liều gián đoạn https://news.medxy.ai/miricorilant-in-metabolic-dysfunction-associated-steatohepatitis-promising-phase-1b-results-highlight-intermittent-dosing-strategy/Medxy AIen2026-11-01T02:26:18-08:00Miricorilant in Metabolic Dysfunction-Associated Steatohepatitis: Promising Phase 1b Results Highlight Intermittent Dosing Strategy https://news.medxy.ai/zh/dopamine-antagonists-in-huntingtons-disease/Medxy AIzh2026-11-01T02:25:38-08:00亨廷顿病中的多巴胺拮抗剂：来自安慰剂对照试验 PROOF-HD 的证据 https://news.medxy.ai/ja/dopamine-antagonists-in-huntingtons/Medxy AIja2026-11-01T02:25:17-08:00ハンチントン病における抗ドパミン薬：プラセボ対照試験「PROOF-HD」からのエビデンス https://news.medxy.ai/vi/dopamine-antagonists-huntingtons/Medxy AIvi2026-11-01T02:24:51-08:00Thuốc kháng dopamin trong bệnh Huntington: Bằng chứng từ thử nghiệm đối chứng giả dược PROOF-HD https://news.medxy.ai/antidopaminergic-medications-and-clinical-outcomes-in-huntington-disease-insights-from-the-proof-hd-placebo-controlled-trial/Medxy AIen2026-11-01T02:24:30-08:00Antidopaminergic Medications and Clinical Outcomes in Huntington Disease: Insights From the PROOF-HD Placebo-Controlled Trial https://news.medxy.ai/zh/lonapegsomatropin-turner-syndrome-52-week-results/Medxy AIzh2026-11-01T02:23:34-08:00每周一次 Lonapegsomatropin 在 Turner 综合征中的疗效与每日 Somatropin 相当：New InsiGHTS 试验52周结果 https://news.medxy.ai/ja/lonapegsomatropin-for-turner-syndrome/Medxy AIja2026-11-01T02:23:17-08:00Turner syndrome に対する週1回 lonapegsomatropin 療法、日次 somatropin と同等の有効性を示す：New InsiGHTS 試験52週成績 https://news.medxy.ai/vi/weekly-lonapegsomatropin-turner-syndrome/Medxy AIvi2026-11-01T02:22:54-08:00Lonapegsomatropin dùng một lần mỗi tuần cho hiệu quả tương đương somatropin hằng ngày ở hội chứng Turner: Kết quả 52 tuần từ thử nghiệm New InsiGHTS https://news.medxy.ai/lonapegsomatropin-once-weekly-therapy-shows-comparable-efficacy-to-daily-somatropin-in-turner-syndrome-52-week-outcomes-from-the-new-insights-trial/Medxy AIen2026-11-01T02:22:36-08:00Lonapegsomatropin Once-Weekly Therapy Shows Comparable Efficacy to Daily Somatropin in Turner Syndrome: 52-Week Outcomes from the New InsiGHTS Trial https://news.medxy.ai/zh/early-cholesterol-treatment/Medxy AIzh2026-11-01T02:21:58-08:00家族性高胆固醇血症的早期降胆固醇治疗：来自SAFEHEART研究的启示 https://news.medxy.ai/ja/early-cholesterol-lowering-therapy/Medxy AIja2026-11-01T02:21:41-08:00家族性高コレステロール血症に対する早期脂質低下療法：SAFEHEART研究が示す知見 https://news.medxy.ai/vi/early-cholesterol-treatment-safeheart/Medxy AIvi2026-11-01T02:21:18-08:00Điều trị hạ cholesterol sớm trong tăng cholesterol máu gia đình: Những phát hiện từ nghiên cứu SAFEHEART https://news.medxy.ai/early-cholesterol-lowering-therapy-in-familial-hypercholesterolaemia-insights-from-the-safeheart-study/Medxy AIen2026-11-01T02:20:58-08:00Early Cholesterol-Lowering Therapy in Familial Hypercholesterolaemia: Insights from the SAFEHEART Study https://news.medxy.ai/zh/digital-knee-pain-therapy-2/Medxy AIzh2026-11-01T02:20:13-08:00数字疗法可显著减轻慢性髌股关节疼痛 https://news.medxy.ai/ja/digital-knee-pain-therapy/Medxy AIja2026-11-01T02:19:53-08:00運動療法と認知行動療法を統合したデジタル治療が慢性膝蓋大腿痛を有意に軽減　多施設RCT https://news.medxy.ai/vi/digital-therapy-knee-pain/Medxy AIvi2026-11-01T02:19:28-08:00Liệu pháp số tích hợp tập luyện và nhận thức–hành vi giúp giảm rõ rệt đau xương bánh chè–đùi mạn tính: Thử nghiệm ngẫu nhiên đa trung tâm https://news.medxy.ai/integrated-digital-therapeutic-combining-exercise-and-cognitive-behavioural-therapy-significantly-reduces-chronic-patellofemoral-pain-a-multicentre-rct/Medxy AIen2026-11-01T02:19:10-08:00Integrated Digital Therapeutic Combining Exercise and Cognitive-Behavioural Therapy Significantly Reduces Chronic Patellofemoral Pain: A Multicentre RCT https://news.medxy.ai/zh/innovative-bedside-vision-rehab/Medxy AIzh2026-11-01T02:18:28-08:00脑损伤康复中的创新床旁计算机视觉：提升姿势评估的新方案 https://news.medxy.ai/ja/posture-assessment-rehabilitation/Medxy AIja2026-11-01T02:18:09-08:00脳損傷リハビリテーションにおける姿勢評価を高める、革新的なポイント・オブ・ケア・コンピュータービジョン https://news.medxy.ai/vi/point-of-care-posture-assessment/Medxy AIvi2026-11-01T02:17:49-08:00Đánh giá tư thế tại điểm chăm sóc bằng thị giác máy tính: Bước tiến mới trong phục hồi chức năng sau tổn thương não https://news.medxy.ai/innovative-point-of-care-computer-vision-for-enhanced-postural-assessment-in-brain-injury-rehabilitation/Medxy AIen2026-11-01T02:17:32-08:00Innovative Point-of-Care Computer Vision for Enhanced Postural Assessment in Brain Injury Rehabilitation https://news.medxy.ai/zh/canestat-enamel-protection/Medxy AIzh2026-11-01T02:16:56-08:00CaneStat 如何增强釉小皮特性并保护釉质免受侵蚀：一项体内与生物物理学分析 https://news.medxy.ai/ja/canestat-enamel-protection-2/Medxy AIja2026-11-01T02:16:29-08:00CaneStatがエナメルペリクルを強化し、エナメル質侵食から守る役割：in vivo・生物物理学的解析 https://news.medxy.ai/vi/canestat-protects-enamel-teeth/Medxy AIvi2026-11-01T02:16:00-08:00CaneStat cải thiện đặc tính pellicle và bảo vệ men răng khỏi mòn: Phân tích in vivo và lý sinh https://news.medxy.ai/canestats-role-in-enhancing-pellicle-properties-and-protecting-enamel-from-erosion-an-in-vivo-and-biophysical-analysis/Medxy AIen2026-11-01T02:15:40-08:00CaneStat’s Role in Enhancing Pellicle Properties and Protecting Enamel From Erosion: An In Vivo and Biophysical Analysis https://news.medxy.ai/zh/pd-l1-negative-nsclc-breakthrough/Medxy AIzh2026-11-01T02:14:54-08:00PD-L1阴性晚期非鳞状NSCLC一线治疗迎来新突破：sacituzumab tirumotecan联合pembrolizumab https://news.medxy.ai/ja/first-line-therapy-potential/Medxy AIja2026-11-01T02:14:33-08:00PD-L1陰性進行非扁平上皮NSCLCに新局面：sacituzumab tirumotecan＋pembrolizumabが示す一次治療の可能性 https://news.medxy.ai/vi/sacituzumab-pembrolizumab-nsclc/Medxy AIvi2026-11-01T02:14:07-08:00Sacituzumab Tirumotecan kết hợp Pembrolizumab ở NSCLC tiến triển không phải tế bào vảy âm tính với PD-L1: Bước ngoặt trong điều trị hàng đầu https://news.medxy.ai/sacituzumab-tirumotecan-plus-pembrolizumab-in-pd-l1-negative-advanced-non-squamous-nsclc-a-paradigm-shift-in-first-line-therapy/Medxy AIen2026-11-01T02:13:46-08:00Sacituzumab Tirumotecan Plus Pembrolizumab in PD-L1-Negative Advanced Non-Squamous NSCLC: A Paradigm Shift in First-Line Therapy https://news.medxy.ai/zh/hope4abi-sexual-health/Medxy AIzh2026-10-31T06:04:24-07:00HOPE4ABI 数字化干预的可行性与影响：改善卒中及脑损伤后心理与性健康 https://news.medxy.ai/ja/hope4abi-digital-intervention/Medxy AIja2026-10-31T06:04:00-07:00HOPE4ABIの実現可能性と臨床的意義：脳卒中・脳損傷後の心と性のウェルビーイングを支えるデジタル介入 https://news.medxy.ai/vi/hope4abi-intervention-feasibility/Medxy AIvi2026-10-31T06:03:33-07:00HOPE4ABI: Can thiệp số hỗ trợ sức khỏe tinh thần và tình dục sau đột quỵ, tổn thương não có khả thi và hứa hẹn đến đâu? https://news.medxy.ai/feasibility-and-impact-of-hope4abi-a-digital-intervention-enhancing-mental-and-sexual-wellbeing-post-stroke-and-brain-injury/Medxy AIen2026-10-31T06:03:09-07:00Feasibility and Impact of HOPE4ABI: A Digital Intervention Enhancing Mental and Sexual Wellbeing Post-Stroke and Brain Injury https://news.medxy.ai/zh/cost-effectiveness-of-nonsurgical-periodontal-therapy/Medxy AIzh2026-10-31T06:02:30-07:00一般牙科实践中非手术牙周治疗的成本效益比较 https://news.medxy.ai/ja/cost-effectiveness-in-nonsurgical-periodontal-therapy/Medxy AIja2026-10-31T06:02:07-07:00一般歯科診療における非外科的歯周治療の費用対効果の比較 https://news.medxy.ai/vi/cost-effectiveness-of-nonsurgical-periodontal-therapy-2/Medxy AIvi2026-10-31T06:01:43-07:00So sánh hiệu quả chi phí của các liệu pháp nha chu không phẫu thuật trong thực hành tổng quát https://news.medxy.ai/comparative-cost-effectiveness-of-non-surgical-periodontal-therapies-in-general-practice/Medxy AIen2026-10-31T06:01:20-07:00Comparative Cost-Effectiveness of Non-Surgical Periodontal Therapies in General Practice https://news.medxy.ai/zh/refractory-colorectal-cancer-treatment/Medxy AIzh2026-10-31T06:00:41-07:00难治性转移性结直肠癌简化14天曲氟尿苷-替吡嘧啶联合贝伐珠单抗方案的非劣效性：PRABITAS试验解读 https://news.medxy.ai/ja/prabitas-trial-colorectal-cancer/Medxy AIja2026-10-31T06:00:12-07:00難治性転移性大腸がんに対するトリフルリジン・チピラシル＋ベバシズマブ14日間簡略レジメンの非劣性：PRABITAS試験からの知見 https://news.medxy.ai/vi/14-day-trifluridine-tipiracil-bevacizumab-regimen/Medxy AIvi2026-10-31T05:59:39-07:00Phác đồ 14 ngày trifluridine-tipiracil + bevacizumab: hiệu quả không kém hơn và ít độc tính hơn trong ung thư đại trực tràng di căn kháng trị https://news.medxy.ai/non-inferiority-of-a-simplified-14-day-trifluridine-tipiracil-plus-bevacizumab-regimen-for-refractory-metastatic-colorectal-cancer-insights-from-the-prabitas-trial/Medxy AIen2026-10-31T05:59:14-07:00Non-Inferiority of a Simplified 14-Day Trifluridine-Tipiracil plus Bevacizumab Regimen for Refractory Metastatic Colorectal Cancer: Insights from the PRABITAS Trial https://news.medxy.ai/ja/immunogenicity-and-safety/Medxy AIja2026-10-31T05:58:36-07:00思春期者におけるPHH-1V COVID-19ワクチンの異種ブースターとしての免疫原性と安全性 https://news.medxy.ai/vi/phh-1v-booster-adolescents/Medxy AIvi2026-10-31T05:58:09-07:00PHH-1V: Liều nhắc lại dị loại an toàn và sinh miễn dịch mạnh ở thanh thiếu niên https://news.medxy.ai/immunogenicity-and-safety-of-phh-1v-covid-19-vaccine-as-a-heterologous-booster-in-adolescents/Medxy AIen2026-10-31T05:57:48-07:00Immunogenicity and Safety of PHH-1V COVID-19 Vaccine as a Heterologous Booster in Adolescents https://news.medxy.ai/zh/immune-changes-before-arthritis/Medxy AIzh2026-10-31T05:57:14-07:00解码即将发病的类风湿关节炎中临床滑膜炎前的免疫学变化 https://news.medxy.ai/ja/immune-changes-before-rheumatoid-arthritis/Medxy AIja2026-10-31T05:56:50-07:00発症直前の関節リウマチにおける臨床滑膜炎前の免疫変化を読み解く https://news.medxy.ai/vi/preclinical-rheumatoid-arthritis/Medxy AIvi2026-10-31T05:56:23-07:00Giải mã những biến đổi miễn dịch trước khi viêm màng hoạt dịch lâm sàng xuất hiện trong viêm khớp dạng thấp sắp khởi phát https://news.medxy.ai/decoding-immunological-changes-preceding-clinical-synovitis-in-imminent-rheumatoid-arthritis/Medxy AIen2026-10-31T05:55:58-07:00Decoding Immunological Changes Preceding Clinical Synovitis in Imminent Rheumatoid Arthritis https://news.medxy.ai/zh/low-cost-organ-preservation/Medxy AIzh2026-10-31T05:55:20-07:00器官保存迎来新突破：超低成本开源常温体外灌注平台 https://news.medxy.ai/ja/low-cost-organ-preservation-2/Medxy AIja2026-10-31T05:54:59-07:00超低コスト・オープンソースで切り拓く臓器保存：常温体外灌流プラットフォームの革新 https://news.medxy.ai/vi/breakthrough-organ-preservation/Medxy AIvi2026-10-31T05:54:38-07:00Đột phá trong bảo tồn cơ quan: Nền tảng tưới máu ngoài cơ thể ở nhiệt độ sinh lý mã nguồn mở, chi phí siêu thấp https://news.medxy.ai/revolutionizing-organ-preservation-an-ultra-low-cost-open-source-normothermic-ex-vivo-perfusion-platform/Medxy AIen2026-10-31T05:54:17-07:00Revolutionizing Organ Preservation: An Ultra-low-cost, Open-source Normothermic Ex Vivo Perfusion Platform https://news.medxy.ai/zh/pediatric-lupus-progression-risk/Medxy AIzh2026-10-31T05:53:42-07:00儿童盘状红斑狼疮进展为系统性红斑狼疮的风险：来自多中心队列研究的启示 https://news.medxy.ai/ja/pediatric-lupus-progression-risk-3/Medxy AIja2026-10-31T05:53:16-07:00小児円板状エリテマトーデスが全身性エリテマトーデスへ進展するリスク：多施設コホート研究からの示唆 https://news.medxy.ai/vi/pediatric-lupus-progression/Medxy AIvi2026-10-31T05:52:46-07:00Nguy cơ tiến triển từ ban đỏ dạng đĩa ở trẻ em sang lupus ban đỏ hệ thống: Những phát hiện từ một nghiên cứu đoàn hệ đa trung tâm https://news.medxy.ai/risk-of-progression-from-pediatric-discoid-lupus-erythematosus-to-systemic-lupus-erythematosus-insights-from-a-multicenter-cohort-study/Medxy AIen2026-10-31T05:52:22-07:00Risk of Progression from Pediatric Discoid Lupus Erythematosus to Systemic Lupus Erythematosus: Insights from a Multicenter Cohort Study https://news.medxy.ai/zh/upper-eyelid-surgery-insights/Medxy AIzh2026-10-31T05:51:42-07:00上睑手术新视角：来自显微解剖研究的启示 https://news.medxy.ai/ja/microscopic-upper-eyelid-anatomy/Medxy AIja2026-10-31T05:51:20-07:00顕微鏡で見直す上眼瞼解剖：上眼瞼形成術の精度を高める新知見 https://news.medxy.ai/vi/upper-eyelid-anatomy-insights/Medxy AIvi2026-10-31T05:50:52-07:00Tạo hình mí trên dưới góc nhìn mới: những hiểu biết từ nghiên cứu giải phẫu vi thể https://news.medxy.ai/revolutionizing-upper-eyelid-surgery-insights-from-microscopic-anatomical-studies/Medxy AIen2026-10-31T05:50:31-07:00Revolutionizing Upper Eyelid Surgery: Insights from Microscopic Anatomical Studies https://news.medxy.ai/zh/multimodal-depression-relapse-prediction/Medxy AIzh2026-10-31T05:49:57-07:00多模态机器学习预测重性抑郁障碍复发：现有证据与未来方向 https://news.medxy.ai/ja/multimodal-for-depression-relapse-prediction/Medxy AIja2026-10-31T05:49:31-07:00マルチモーダル機械学習による大うつ病性障害の再発予測：既存のエビデンスと今後の展望 https://news.medxy.ai/vi/predicting-depression-relapse/Medxy AIvi2026-10-31T05:48:59-07:00Dự đoán tái phát trong rối loạn trầm cảm chủ yếu bằng học máy đa mô thức: Bằng chứng hiện nay và định hướng tương lai https://news.medxy.ai/multimodal-machine-learning-based-prediction-of-relapse-in-major-depressive-disorder-current-evidence-and-future-directions/Medxy AIen2026-10-31T05:48:34-07:00Multimodal Machine Learning-Based Prediction of Relapse in Major Depressive Disorder: Current Evidence and Future Directions https://news.medxy.ai/zh/machine-learning-ards-prediction/Medxy AIzh2026-10-31T05:47:50-07:00机器学习赋能胸片识别ARDS：可独立预测机械通气患者结局 https://news.medxy.ai/ja/ai-ards-detection/Medxy AIja2026-10-31T05:47:28-07:00AIで胸部X線を解析したARDS検出は、人工呼吸管理中患者の転帰予測を高める https://news.medxy.ai/vi/machine-learning-ards-prediction-2/Medxy AIvi2026-10-31T05:47:03-07:00Phát hiện ARDS trên phim X-quang bằng Machine Learning giúp dự báo kết cục ở bệnh nhân thở máy https://news.medxy.ai/machine-learning-enhanced-radiographic-detection-of-ards-predicts-outcomes-in-mechanically-ventilated-patients/Medxy AIen2026-10-31T05:46:39-07:00Machine Learning-Enhanced Radiographic Detection of ARDS Predicts Outcomes in Mechanically Ventilated Patients https://news.medxy.ai/zh/sustaining-insomnia-care/Medxy AIzh2026-10-31T05:45:58-07:00VA 初级保健心理健康门诊失眠照护如何实现持续：撤除实施支持对治疗提供与用药的影响 https://news.medxy.ai/ja/behavioral-insomnia-care-sustainability/Medxy AIja2026-10-31T05:45:33-07:00VAのPCMHIクリニックにおける行動的不眠ケアの持続：実装支援中止が治療提供と薬剤使用に及ぼす影響 https://news.medxy.ai/vi/maintaining-insomnia-care/Medxy AIvi2026-10-31T05:45:10-07:00Duy trì chăm sóc mất ngủ bằng liệu pháp hành vi tại các phòng khám PCMHI của VA: Tác động của việc rút chiến lược triển khai lên cung cấp điều trị và sử dụng thuốc https://news.medxy.ai/sustaining-behavioral-insomnia-care-in-va-pcmhi-clinics-impact-of-implementation-strategy-withdrawal-on-treatment-delivery-and-medication-use/Medxy AIen2026-10-31T05:44:48-07:00Sustaining Behavioral Insomnia Care in VA PCMHI Clinics: Impact of Implementation Strategy Withdrawal on Treatment Delivery and Medication Use https://news.medxy.ai/zh/relieving-t-cell-exhaustion/Medxy AIzh2026-10-31T05:44:14-07:00缓解 CD8 T 细胞耗竭：克服大 B 细胞淋巴瘤中 CAR T 细胞治疗失败的新策略 https://news.medxy.ai/ja/overcoming-car-t-cell-therapy-failure/Medxy AIja2026-10-31T05:43:47-07:00CD8陽性T細胞疲弊を標的に、CAR T細胞療法不成功を克服する：大細胞型B細胞リンパ腫における新たな戦略 https://news.medxy.ai/vi/reduce-cd8-t-cell-exhaustion/Medxy AIvi2026-10-31T05:43:18-07:00Giảm kiệt quệ tế bào T CD8 để khắc phục thất bại của liệu pháp CAR T-cell trong u lympho tế bào B lớn https://news.medxy.ai/mitigating-cd8-t-cell-exhaustion-to-overcome-car-t-cell-therapy-failure-in-large-b-cell-lymphoma/Medxy AIen2026-10-31T05:42:50-07:00Mitigating CD8 T-cell Exhaustion to Overcome CAR T-cell Therapy Failure in Large B-cell Lymphoma https://news.medxy.ai/zh/interstitial-lung-disease-diagnosis/Medxy AIzh2026-10-31T05:42:15-07:00提升间质性肺疾病诊断：支气管内光学相干断层成像在多学科评估中的作用 https://news.medxy.ai/ja/bronchial-optical-coherence-tomography/Medxy AIja2026-10-31T05:41:48-07:00間質性肺疾患診断を高める新たな視点：多職種評価における気管支内光干渉断層撮影の役割 https://news.medxy.ai/vi/interstitial-lung-disease-diagnosis-2/Medxy AIvi2026-10-31T05:41:18-07:00Nâng cao chẩn đoán bệnh phổi kẽ: Vai trò của chụp cắt lớp kết hợp quang học qua nội phế quản trong đánh giá đa chuyên khoa https://news.medxy.ai/enhancing-interstitial-lung-disease-diagnosis-the-role-of-endobronchial-optical-coherence-tomography-in-multidisciplinary-evaluation/Medxy AIen2026-10-31T05:40:52-07:00Enhancing Interstitial Lung Disease Diagnosis: The Role of Endobronchial Optical Coherence Tomography in Multidisciplinary Evaluation https://news.medxy.ai/zh/ophthalmology-residency-clinic-reform/Medxy AIzh2026-10-31T05:40:15-07:00重塑眼科住院医师门诊：促进健康公平并提升住院医师手术经验 https://news.medxy.ai/ja/ophthalmology-residency-clinic-reform-2/Medxy AIja2026-10-31T05:39:52-07:00眼科レジデント外来の再構築：健康の公平性促進とレジデントの外科的経験の向上 https://news.medxy.ai/vi/reform-in-ophthalmology-residency-clinic/Medxy AIvi2026-10-31T05:39:26-07:00Tái định hình các phòng khám dành cho bác sĩ nội trú chuyên ngành nhãn khoa: Thúc đẩy công bằng y tế và nâng cao trải nghiệm phẫu thuật cho bác sĩ nội trú https://news.medxy.ai/transforming-resident-eye-clinics-enhancing-health-equity-and-resident-surgical-experience/Medxy AIen2026-10-31T05:39:01-07:00Transforming Resident Eye Clinics: Enhancing Health Equity and Resident Surgical Experience https://news.medxy.ai/zh/tonsil-video-assessment-sleep-disorders/Medxy AIzh2026-10-31T05:38:23-07:00儿童睡眠呼吸障碍的扁桃体视频评估：进展、挑战与临床意义 https://news.medxy.ai/ja/video-based-tonsil-assessment/Medxy AIja2026-10-31T05:37:56-07:00小児の睡眠呼吸障害における扁桃サイズ評価を動画で行う新手法：進展、課題、臨床的意義 https://news.medxy.ai/vi/tonsil-size-assessment/Medxy AIvi2026-10-31T05:37:24-07:00Đánh giá kích thước amidan ở trẻ rối loạn hô hấp khi ngủ bằng video: tiến bộ, thách thức và ý nghĩa lâm sàng https://news.medxy.ai/video-based-assessment-of-tonsil-size-in-children-with-sleep-disordered-breathing-advances-challenges-and-clinical-implications/Medxy AIen2026-10-31T05:36:56-07:00Video-Based Assessment of Tonsil Size in Children With Sleep-Disordered Breathing: Advances, Challenges, and Clinical Implications https://news.medxy.ai/zh/pancreatic-vein-resection-study/Medxy AIzh2026-10-31T05:36:10-07:00胰腺癌手术中门静脉肠系膜静脉切除：切线性与节段性方式的全球队列研究新发现 https://news.medxy.ai/ja/pancreatic-vein-resection-study-2/Medxy AIja2026-10-31T05:35:43-07:00膵がん手術における門静脈・腸間膜静脈切除：切線切除と区域切除に関する国際コホート研究の新たな知見 https://news.medxy.ai/vi/portal-mesenteric-resection-techniques/Medxy AIvi2026-10-31T05:35:16-07:00Cắt tĩnh mạch cửa–mạc treo tràng trên tiếp tuyến hay cắt đoạn trong phẫu thuật ung thư tụy: Kết luận từ một nghiên cứu đoàn hệ toàn cầu https://news.medxy.ai/tangential-versus-segmental-portomesenteric-venous-resection-in-pancreatic-cancer-surgery-insights-from-a-global-cohort-study/Medxy AIen2026-10-31T05:34:51-07:00Tangential Versus Segmental Portomesenteric Venous Resection in Pancreatic Cancer Surgery: Insights from a Global Cohort Study https://news.medxy.ai/zh/meningioma-risk-assessment/Medxy AIzh2026-10-31T05:34:14-07:00雌孕激素与单孕激素治疗使用者的脑膜瘤风险评估：来自 EudraVigilance 药物警戒数据的启示 https://news.medxy.ai/ja/meningioma-risk-assessment-2/Medxy AIja2026-10-31T05:33:48-07:00エストロゲン・プロゲスチン製剤とプロゲスチン単剤療法における髄膜腫リスク評価：EudraVigilance ファーマコビジランスデータからの知見 https://news.medxy.ai/vi/meningioma-risk-hormone-therapy/Medxy AIvi2026-10-31T05:33:19-07:00Đánh giá nguy cơ u màng não ở người dùng liệu pháp estro-progestin và progestin đơn độc: Góc nhìn từ dữ liệu cảnh giác dược EudraVigilance https://news.medxy.ai/evaluating-meningioma-risk-in-users-of-estro-progestin-and-progestin-only-therapies-insights-from-eudravigilance-pharmacovigilance-data/Medxy AIen2026-10-31T05:32:54-07:00Evaluating Meningioma Risk in Users of Estro-Progestin and Progestin-only Therapies: Insights from EudraVigilance Pharmacovigilance Data https://news.medxy.ai/zh/targeting-mevalonate-biosynthesis/Medxy AIzh2026-10-31T05:32:15-07:00靶向甲羟戊酸生物合成：对抗吉西他滨耐药性胰腺癌的新策略 https://news.medxy.ai/ja/gemcitabine-resistant-pancreatic-cancer/Medxy AIja2026-10-31T05:31:51-07:00ゲムシタビン耐性膵癌を狙う新戦略：メバロン酸生合成経路への着目 https://news.medxy.ai/vi/targeting-mevalonate-biosynthesis-2/Medxy AIvi2026-10-31T05:31:24-07:00Nhắm vào sinh tổng hợp mevalonate: chiến lược mới chống ung thư tụy kháng gemcitabine https://news.medxy.ai/targeting-mevalonate-biosynthesis-a-novel-strategy-against-gemcitabine-resistant-pancreatic-cancer/Medxy AIen2026-10-31T05:31:03-07:00Targeting Mevalonate Biosynthesis: A Novel Strategy Against Gemcitabine-resistant Pancreatic Cancer https://news.medxy.ai/zh/blood-biomarkers-dementia-prediction/Medxy AIzh2026-10-31T05:30:25-07:00血液生物标志物能否用于痴呆长期预测？——Whitehall II 队列研究带来的启示 https://news.medxy.ai/ja/blood-biomarkers-predict-dementia/Medxy AIja2026-10-31T05:30:01-07:00血液バイオマーカーで認知症を長期予測できるか：Whitehall II コホートから得られた知見 https://news.medxy.ai/vi/blood-biomarkers-predict-dementia-whitehall-ii/Medxy AIvi2026-10-31T05:29:31-07:00Các dấu ấn sinh học trong máu có thể được sử dụng để dự đoán chứng sa sút trí tuệ trong dài hạn không? — Những thông tin từ nghiên cứu đoàn hệ Whitehall II https://news.medxy.ai/evaluating-blood-based-biomarkers-for-long-term-prediction-of-dementia-insights-from-the-whitehall-ii-cohort/Medxy AIen2026-10-31T05:29:08-07:00Evaluating Blood-Based Biomarkers for Long-Term Prediction of Dementia: Insights from the Whitehall II Cohort https://news.medxy.ai/zh/muscle-lipid-metabolism-disorders/Medxy AIzh2026-10-31T05:28:33-07:00男性性腺功能减退中的骨骼肌与脂质代谢紊乱：来自干预性代谢组学分析的启示 https://news.medxy.ai/ja/lipid-metabolism-hypogonadism-in-men/Medxy AIja2026-10-31T05:28:08-07:00男性性腺機能低下症における骨格筋および脂質代謝の異常：介入的メタボロミクス解析からの示唆 https://news.medxy.ai/vi/lipid-metabolism-hypogonadism-men/Medxy AIvi2026-10-31T05:27:40-07:00Rối loạn chuyển hóa lipid và cơ xương ở nam giới thiểu năng sinh dục: Góc nhìn từ phân tích metabolomic can thiệp https://news.medxy.ai/skeletal-muscle-and-lipid-metabolism-disruption-in-male-hypogonadism-insights-from-interventional-metabolomic-profiling/Medxy AIen2026-10-31T05:27:15-07:00Skeletal Muscle and Lipid Metabolism Disruption in Male Hypogonadism: Insights from Interventional Metabolomic Profiling https://news.medxy.ai/zh/smart-reach2-model/Medxy AIzh2026-10-31T05:26:37-07:00SMART-REACH2：用于预测终生心血管风险并优化已确诊动脉粥样硬化性心血管疾病预防治疗的全球模型 https://news.medxy.ai/ja/smart-reach2-risk-prediction-model/Medxy AIja2026-10-31T05:26:15-07:00SMART-REACH2：生涯にわたる心血管リスクを予測し、動脈硬化性心血管疾患と診断された患者に対する予防・治療を最適化するためのグローバルモデル https://news.medxy.ai/vi/smart-reach2-risk-model/Medxy AIvi2026-10-31T05:25:50-07:00SMART-REACH2: Một mô hình toàn cầu giúp dự đoán nguy cơ tim mạch suốt đời và tối ưu hóa điều trị dự phòng ở những bệnh nhân đã mắc bệnh tim mạch do xơ vữa https://news.medxy.ai/smart-reach2-a-global-model-for-predicting-lifetime-cardiovascular-risk-and-tailoring-preventive-therapy-in-established-atherosclerotic-disease/Medxy AIen2026-10-31T05:25:28-07:00SMART-REACH2: A Global Model for Predicting Lifetime Cardiovascular Risk and Tailoring Preventive Therapy in Established Atherosclerotic Disease